JPS5522636A - Thiazoliding derivative - Google Patents

Thiazoliding derivative

Info

Publication number
JPS5522636A
JPS5522636A JP9567378A JP9567378A JPS5522636A JP S5522636 A JPS5522636 A JP S5522636A JP 9567378 A JP9567378 A JP 9567378A JP 9567378 A JP9567378 A JP 9567378A JP S5522636 A JPS5522636 A JP S5522636A
Authority
JP
Japan
Prior art keywords
formula
group
alkylene group
thiazolidine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP9567378A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6242903B2 (index.php
Inventor
Yutaka Kawamatsu
Takeshi Fujita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14144012&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS5522636(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP9567378A priority Critical patent/JPS5522636A/ja
Priority to US06/062,512 priority patent/US4287200A/en
Priority to DK325079A priority patent/DK149023C/da
Priority to ES483077A priority patent/ES8102107A1/es
Priority to CA333,148A priority patent/CA1131644A/en
Priority to EP79301564A priority patent/EP0008203B1/en
Priority to DE7979301564T priority patent/DE2963585D1/de
Publication of JPS5522636A publication Critical patent/JPS5522636A/ja
Priority to US06/258,554 priority patent/US4340605A/en
Priority to US06/396,093 priority patent/US4438141A/en
Priority to US06/476,017 priority patent/US4444779A/en
Publication of JPS6242903B2 publication Critical patent/JPS6242903B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP9567378A 1978-08-04 1978-08-04 Thiazoliding derivative Granted JPS5522636A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP9567378A JPS5522636A (en) 1978-08-04 1978-08-04 Thiazoliding derivative
US06/062,512 US4287200A (en) 1978-08-04 1979-07-27 Thiazolidine derivatives
DK325079A DK149023C (da) 1978-08-04 1979-08-01 Analogifremgangsmaade til fremstilling af tiazolidinderivater
ES483077A ES8102107A1 (es) 1978-08-04 1979-08-02 Un procedimiento para la obtencion de un derivado de tiazo- lidina
DE7979301564T DE2963585D1 (en) 1978-08-04 1979-08-03 Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
CA333,148A CA1131644A (en) 1978-08-04 1979-08-03 Thiazolidine derivatives
EP79301564A EP0008203B1 (en) 1978-08-04 1979-08-03 Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
US06/258,554 US4340605A (en) 1978-08-04 1981-04-29 Thiazolidine derivatives
US06/396,093 US4438141A (en) 1978-08-04 1982-07-07 Thiazolidine derivatives
US06/476,017 US4444779A (en) 1978-08-04 1983-03-15 Thiazolidine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9567378A JPS5522636A (en) 1978-08-04 1978-08-04 Thiazoliding derivative

Publications (2)

Publication Number Publication Date
JPS5522636A true JPS5522636A (en) 1980-02-18
JPS6242903B2 JPS6242903B2 (index.php) 1987-09-10

Family

ID=14144012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9567378A Granted JPS5522636A (en) 1978-08-04 1978-08-04 Thiazoliding derivative

Country Status (7)

Country Link
US (4) US4287200A (index.php)
EP (1) EP0008203B1 (index.php)
JP (1) JPS5522636A (index.php)
CA (1) CA1131644A (index.php)
DE (1) DE2963585D1 (index.php)
DK (1) DK149023C (index.php)
ES (1) ES8102107A1 (index.php)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
WO1985004171A1 (fr) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant
WO1986002073A1 (fr) * 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
JPS61286376A (ja) * 1985-06-10 1986-12-16 Takeda Chem Ind Ltd チアゾリジン誘導体およびそれを含んでなる医薬組成物
WO1992014719A1 (fr) * 1991-02-25 1992-09-03 Kyorin Pharmaceutical Co., Ltd. Derive de thiazolidine-2, 4, sel dudit derive et leur production
JPH05213913A (ja) * 1991-08-20 1993-08-24 Adir 新規な２，４−チアゾリジンジオン化合物およびこれらの化合物を含有する医薬組成物
EP0590793A1 (en) 1992-08-31 1994-04-06 Sankyo Company Limited Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
JPH0714924B2 (ja) * 1990-06-05 1995-02-22 フアイザー・インコーポレイテツド 血糖低下性及び血液コレステロール低下性オキサゾリジンジオン化合物
JP2010539171A (ja) * 2007-09-14 2010-12-16 メタボリック ソリューションズ ディベロップメント カンパニー 高血圧を処置するためのチアゾリジンジオン類似体
WO2011059053A1 (ja) 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
JPS6143114A (ja) * 1984-08-03 1986-03-01 Takeda Chem Ind Ltd 虹彩・毛様体疾患治療用眼局所投与剤
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
US4738972A (en) * 1985-05-21 1988-04-19 Pfizer Inc. Hypoglycemic thiazolidinediones
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
US5691367A (en) * 1985-08-09 1997-11-25 Eli Lilly And Company Aryl-substituted rhodanine derivatives
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
HU203330B (en) * 1987-06-10 1991-07-29 Pfizer Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5521201A (en) * 1987-09-04 1996-05-28 Beecham Group P.L.C. Method for treatment of atherosclerosis
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5130379A (en) * 1988-03-08 1992-07-14 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5036079A (en) * 1989-12-07 1991-07-30 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5216002A (en) * 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
KR0170416B1 (ko) * 1990-02-09 1999-02-18 로버트 에이. 아미테이지 고혈압 치료를 위한 인슐린 증감제의 용도
ATE205206T1 (de) * 1990-04-27 2001-09-15 Sankyo Co Benzylidenthiazolidinderivate, ihre herstellung und ihre anwendung als lipidperoxid-inhibitoren
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5334604A (en) * 1990-08-23 1994-08-02 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH0445604U (index.php) * 1990-08-24 1992-04-17
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
HUT68370A (en) * 1991-04-11 1995-06-28 Takeda Chemical Industries Ltd Thiazolidine derivatives, pharmaceutical compositions containing them and process for their production
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
TW222626B (index.php) 1991-07-22 1994-04-21 Pfizer
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
NO302519B1 (no) * 1991-12-26 1998-03-16 Sankyo Co Tiazolidinforbindelser som inneholder en kinongruppe, og farmasöytisk preparat
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5498621A (en) * 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
IL106877A (en) * 1992-09-10 1998-03-10 Lilly Co Eli Rhodanine derivatives for use as medicaments for the treatment of alzheimer's disease
FR2696743B1 (fr) * 1992-10-12 1994-12-23 Adir Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant.
TW245716B (index.php) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
US5591862A (en) * 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
AU679572B2 (en) * 1993-09-15 1997-07-03 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of NIDDM
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
AU749416B2 (en) * 1993-09-15 2002-06-27 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of NIDDM
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5401761A (en) * 1993-12-09 1995-03-28 Pfizer, Inc. Thiazolidinedione hypoglycemic agents
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
IL113084A (en) * 1994-03-23 1999-01-26 Sankyo Co Thiazolidine and oxazolidine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
RU2114844C1 (ru) * 1994-04-11 1998-07-10 Санкио Компани Лимитед Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5703096A (en) 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
JPH09136877A (ja) * 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TW474809B (en) * 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
JPH09323930A (ja) 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
ES2207719T3 (es) * 1996-04-04 2004-06-01 Sankyo Company, Limited Derivados del acido fenilalquilcarboxilico.
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
FR2749583B1 (fr) 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5985884A (en) * 1996-07-01 1999-11-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
AU2995497A (en) * 1996-07-26 1997-11-19 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
DE19711617A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9702305D0 (sv) * 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
NZ501260A (en) * 1997-06-18 2002-09-27 Smithkline Beecham P Treatment of diabetes with thiazolidinedione and metformin
CZ299310B6 (cs) 1997-06-18 2008-06-18 Smithkline Beecham Plc Lécivo pro lécbu diabetes mellitus a stavu spojených s diabetes mellitus
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
HUP0003881A3 (en) 1997-10-02 2001-04-28 Sankyo Co Amidocarboxylic acid derivatives
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9723295D0 (en) 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
DE69939485D1 (de) 1998-11-12 2008-10-16 Smithkline Beecham Plc Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
CA2350599A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
WO2000043006A1 (en) * 1999-01-19 2000-07-27 Sankyo Company, Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
HK1047082B (zh) * 1999-04-01 2008-06-06 埃斯佩里安医疗公司 醚化合物，及其组合物和用途
US6214842B1 (en) 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
EP1194147B1 (en) * 1999-06-18 2007-01-10 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
HK1043113A1 (zh) * 1999-07-01 2002-09-06 Geron Corporation 端粒酶抑制劑及其使用方法
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US6723506B2 (en) 2000-01-20 2004-04-20 Brigham And Women's Hospital Method of identifying PAX8-PPAR gamma-nucleic acid molecules
PT1741445E (pt) 2000-01-21 2013-11-11 Novartis Ag Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
AU2001294673A1 (en) * 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
AU2002211667A1 (en) 2000-10-11 2002-04-22 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US6699910B2 (en) 2000-10-11 2004-03-02 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
WO2002030884A2 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
MXPA03003021A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
CA2439063A1 (en) * 2001-03-12 2002-09-19 Novartis Ag Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
JP4152641B2 (ja) * 2001-08-07 2008-09-17 クラシエ製薬株式会社 チアゾリジン誘導体の副作用軽減剤
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) * 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
BR0309152A (pt) * 2002-04-10 2007-01-30 Esperion Therapeutics Inc composto ou sais, solvatos, hidratos ou pró-drogas deste farmaceuticamente aceitáveis, composição, métodos para tratar ou prevenir uma doença ou condição, uma doença cardiovascular, uma dislipidemia, a hipertensão, o cáncer, a inflamação, e a impotência em um paciente, forma de dosagem unitária, e, método para identificar um composto útil para tratar ou prevenir uma condição em um paciente
WO2004004774A2 (en) * 2002-07-03 2004-01-15 Esperion Therapeutics, Inc. Compositions comprising panthetine for the treatment of dyslipidemia
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
DE60316152D1 (de) * 2002-07-16 2007-10-18 Cadila Healthcare Ltd Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US20040048910A1 (en) * 2002-08-22 2004-03-11 Bove Susan Elizabeth Method of treating osteoarthritis
EP2402300B1 (en) * 2003-01-23 2016-05-25 Esperion Therapeutics Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
JP2007502847A (ja) * 2003-05-13 2007-02-15 シントン・ベスローテン・フェンノートシャップ チアゾリジンジオン誘導体およびその化合物を製造する方法
OA13174A (en) * 2003-05-30 2006-12-13 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors.
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
US20050192347A1 (en) * 2003-12-23 2005-09-01 Dasseux Jean-Louis H. Urea and thiourea compounds and compositions for cholesterol management and related uses
US7705177B2 (en) 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
EP1716144A2 (en) * 2004-02-20 2006-11-02 Synthon B.V. Processes for making pioglitazone and compounds of the processes
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
US20060009487A1 (en) * 2004-06-09 2006-01-12 Sircar Jagadish C Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
RU2006146479A (ru) * 2004-06-09 2008-07-20 Аванир Фармасьютикалс (Us) Небольшие молекулярные медиаторы для лечения гиперхолестеринемии и связанных заболеваний
AR049081A1 (es) * 2004-06-09 2006-06-21 Avanir Pharmaceuticals Mediadores del transporte inverso de colesterol para el tratamiento de la hipercolesterolemia
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
MX2008011872A (es) 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
NZ571871A (en) 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
EP2134169A2 (en) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
CA2688111A1 (en) 2007-05-23 2008-12-04 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
EP2383263B1 (en) * 2008-12-30 2014-04-16 Industry-academic Cooperation Foundation, Chosun University Novel thiazolidinedione derivative and use thereof
PE20161560A1 (es) 2009-09-03 2017-01-11 Pfizer Vaccines Llc Vacuna de pcsk9
PL2513070T3 (pl) 2009-12-15 2018-05-30 Cirius Therapeutics, Inc. Oszczędzające ppar sole tiazolidynodionu do leczenia chorób metabolicznych
US10429384B2 (en) 2010-01-22 2019-10-01 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
CN102946860A (zh) * 2010-04-21 2013-02-27 新陈代谢解决方案开发公司 噻唑烷二酮类似物
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
CA2890086C (en) 2012-11-05 2022-05-31 Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist preferably a thiazolid nedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
WO2016149191A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2020257571A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Methods of making bempedoic acid and compositions of the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3825587A (en) * 1970-05-05 1974-07-23 Rorer Inc William H Substituted phenylacetic acid compounds
US3825553A (en) * 1970-05-05 1974-07-23 Rorer Inc William H Certain 5-arylthiazolidines
CA962269A (en) * 1971-05-05 1975-02-04 Robert E. Grahame (Jr.) Thiazoles, and their use as insecticides
SU480711A1 (ru) * 1973-07-02 1975-08-15 Ленинградский Ордена Трудового Красного Знамени Технологический Институт Им.Ленсовета Способ получени производных 3-оксиметилтиазолиндиона-2,4
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
WO1985004171A1 (fr) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant
WO1985004170A1 (fr) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant
JPS60208980A (ja) * 1984-03-21 1985-10-21 Takeda Chem Ind Ltd チアゾリジンジオン誘導体、その製造法およびそれを含んでなる糖尿病または高脂血症治療剤
WO1986002073A1 (fr) * 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
JPS61286376A (ja) * 1985-06-10 1986-12-16 Takeda Chem Ind Ltd チアゾリジン誘導体およびそれを含んでなる医薬組成物
JPH0714924B2 (ja) * 1990-06-05 1995-02-22 フアイザー・インコーポレイテツド 血糖低下性及び血液コレステロール低下性オキサゾリジンジオン化合物
WO1992014719A1 (fr) * 1991-02-25 1992-09-03 Kyorin Pharmaceutical Co., Ltd. Derive de thiazolidine-2, 4, sel dudit derive et leur production
US5342850A (en) * 1991-02-25 1994-08-30 Kyorin Pharmaceutical Co., Ltd. Thiazolidine-2,4-dione derivatives, their salts and their preparation processes
JPH05213913A (ja) * 1991-08-20 1993-08-24 Adir 新規な２，４−チアゾリジンジオン化合物およびこれらの化合物を含有する医薬組成物
EP0590793A1 (en) 1992-08-31 1994-04-06 Sankyo Company Limited Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
JP2010539171A (ja) * 2007-09-14 2010-12-16 メタボリック ソリューションズ ディベロップメント カンパニー 高血圧を処置するためのチアゾリジンジオン類似体
WO2011059053A1 (ja) 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬
US9492422B2 (en) 2009-11-13 2016-11-15 Toray Industries, Inc. Therapeutic or prophylactic agent for diabetes

Also Published As

Publication number Publication date
DK325079A (da) 1980-02-05
DK149023B (da) 1985-12-23
DK149023C (da) 1986-10-13
ES483077A0 (es) 1980-12-16
US4444779A (en) 1984-04-24
ES8102107A1 (es) 1980-12-16
US4287200A (en) 1981-09-01
EP0008203A1 (en) 1980-02-20
JPS6242903B2 (index.php) 1987-09-10
DE2963585D1 (en) 1982-10-21
CA1131644A (en) 1982-09-14
US4438141A (en) 1984-03-20
EP0008203B1 (en) 1982-08-25
US4340605A (en) 1982-07-20

Similar Documents

Publication Publication Date Title
JPS5522636A (en) Thiazoliding derivative
NO157896C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme tiazolidindion-derivater.
JPS5681578A (en) Novel thioalkyl amide derivative
FI881104A0 (fi) Menetelmä antidiabeettisina aineina käytettävien bentsoksatsiinijohdannaisten valmistamiseksi
ATE53034T1 (de) Verfahren zur herstellung von cephemverbindungen.
JPS5564586A (en) Thiazolidine derivative
JPS55133366A (en) Thiazole derivative
GB1364218A (en) N-alkoxy-carbonyl- or n-alkylthiocarbonyl-2-/2 -thienyl/-benzimi dazoles a process for their preparation and their use as fungi cides
DK591185D0 (da) Fremgangsmaade til fremstilling af aminothiazoleddikesyrederivater
JPS56104876A (en) Thiazolidine derivative
JPS5754177A (ja) Chikanchiazoorujudotai
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
SE7901250L (sv) Nytt forfarande for framstellning av tiazolderivat
JPS57106663A (en) 1,4-disubstituted piperazine derivative and its preparation
JPS5690067A (en) Novel heterocyclic ring substituted phenylacetic acid derivative
JPS6438090A (en) Thiazolidine compound
FI850116L (fi) Aminoetyl-imidazol, farmaceutisk produkt innehaollande detta samt dess framstaellningsfoerfarande.
JPS6429369A (en) Oxazoline derivative
IE41311B1 (en) Substituted ethylenylphenoxy-2,2-dimethyl acetic acid derivatives
JPS5643274A (en) Trihalopropane derivative
JPS5731673A (en) Piperazine derivative
JPS5780379A (en) (omega-piperazinylalkoxy)alkylenedioxybenzene and its acid addition salt
KR880006215A (ko) 티아졸 화합물의 제조방법
JPS55344A (en) 2-nitrosoiminobenzthiazoline derivative
JPS56115780A (en) Phenoxyalkaneacid derivative substituted by heterocyclic ring containing nitrogen and sulfur, and its preparation